Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

VitaNova Life Sciences (YJGJ) EBITDA Margin (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed EBITDA Margin for 7 consecutive years, with 23.22% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 179.0% year-over-year to 23.22%, compared with a TTM value of 45.04% through Oct 2025, up 1871.0%, and an annual FY2025 reading of 45.39%, up 936.0% over the prior year.
  • EBITDA Margin was 23.22% for Q4 2025 at VitaNova Life Sciences, up from 31.22% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 83.91% in Q1 2022 and bottomed at 245.77% in Q1 2023.
  • Average EBITDA Margin over 5 years is 13.49%, with a median of 21.43% recorded in 2024.
  • The sharpest move saw EBITDA Margin crashed -32968bps in 2023, then soared 26856bps in 2024.
  • Year by year, EBITDA Margin stood at 66.65% in 2021, then surged by 139bps to 26.01% in 2022, then plummeted by -662bps to 146.17% in 2023, then soared by 115bps to 21.43% in 2024, then increased by 8bps to 23.22% in 2025.
  • Business Quant data shows EBITDA Margin for YJGJ at 23.22% in Q4 2025, 31.22% in Q3 2025, and 55.41% in Q2 2025.